Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles
Graduate School of Biomedical Sciences; W. Harry Feinstone Department of Molecular Microbiology and Immunology; Department of Pathology
Life Sciences | Medicine and Health Sciences
Measles remains a principal cause of worldwide mortality, in part because young infants cannot be immunized effectively. Development of new vaccines has been hindered by previous experience with a formalin-inactivated vaccine that predisposed to a severe form of disease (atypical measles). Here we have developed and tested potential DNA vaccines for immunogenicity, efficacy and safety in a rhesus macaque model of measles. DNA protected from challenge with wild-type measles virus. Protection correlated with levels of neutralizing antibody and not with cytotoxic T lymphocyte activity. There was no evidence in any group, including those receiving hemagglutinin-encoding DNA alone, of 'priming' for atypical measles.
DOI of Published Version
Nat Med. 2000 Jul;6(7):776-81. Link to article on publisher's site
Polack FP, Lee SH, Permar SR, Manyara E, Nousari HG, Jeng Y, Mustafa F, Valsamakis A, Adams RJ, Robinson HL, Griffin DE. (2000). Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. GSBS Student Publications. https://doi.org/10.1038/77506. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/993